Growth investors focus on stocks that are seeing above-average financial growth, as this feature helps these securities garner the market's attention and deliver solid returns. However, it isn't easy to find a great growth stock.By their very nature, these stocks carry above-average risk and volatility. Moreover, if a company's growth story is over or nearing its end, betting on it could lead to significant loss.However, the task of finding cutting-edge growth stocks is made easy with the help of the Zacks ...

APi Group Corporation (NYSE:APG) is included among the 12 Best HVAC Stocks to Buy Now. Truist Names APi Group (APG) Top Pick as Facility Services Demand Holds Firm Photo by NeONBRAND on Unsplash On January 21, Truist raised its price target on APi Group Corporation (NYSE:APG) to $50 from $41 and reaffirmed its Buy rating. The firm said it continues to view the facility services space favorably heading into 2026, describing the sector as “largely insulated” from broader macro swings and AI-related shifts ...

APi will hold a webcast/dial-in conference call to discuss its financial results at 8:30 a.m. (Eastern Time) on Wednesday, February 25, 2026. Participants on the call will include Russell A. Becker, President and Chief Executive Officer; and David Jackola, EVP and Chief Financial Officer. The conference call can be accessed by registering online using the links below. Analysts will receive dial-in information as well as a conference ID once registered. Webcast Link: https://events.q4inc.com/attendee/4318368 ...

Artificial intelligence is the greatest investment opportunity of our lifetime. The time to invest in groundbreaking AI is now, and this stock is a steal! AI is eating the world—and the machines behind it are ravenous. Each ChatGPT query, each model update, each robotic breakthrough consumes massive amounts of energy. In fact, AI is already pushing global power grids to the brink. Wall Street is pouring hundreds of billions into artificial intelligence—training smarter chatbots, automating industries, and b ...

Core Insights - Greystone Capital reported a median account return of +0.3% for Q4 2025 and +2.8% for the full year 2025, both net of fees [1] - Since its inception in Q4 2019, Greystone Capital focuses on identifying mispriced small and microcap securities to build a concentrated portfolio [1] Company Overview - Greystone Capital is a long-only, equity-focused Registered Investment Adviser based in West Chester, PA [1] - The firm emphasizes a fundamental research process aimed at uncovering undervalued small and microcap stocks [1] - Greystone aims to differentiate itself by providing full transparency regarding its investments and aligning its interests with those of its clients [1] Investment Strategy - The investment approach is centered on patience, sound decision-making, and continuous improvement [1] - Client portfolios are managed through concentrated positions in small companies that are often overlooked or misunderstood, which may lead to mispricings [1] - The firm views stocks as ownership shares in businesses and intends to hold these investments for extended periods until mispricings are corrected [1]

Growth stocks are attractive to many investors, as above-average financial growth helps these stocks easily grab the market's attention and produce exceptional returns. However, it isn't easy to find a great growth stock.That's because, these stocks usually carry above-average risk and volatility. In fact, betting on a stock for which the growth story is actually over or nearing its end could lead to significant loss.However, the task of finding cutting-edge growth stocks is made easy with the help of the Z ...

Core Insights - Insider transactions, particularly purchases, are closely monitored by investors as they can indicate a positive long-term outlook for companies [1][9] Micron (MU) - Micron shares have surged nearly 250% over the past year, driven by strong demand related to AI [3] - A director recently purchased approximately 11,600 shares for just under $4 million, reflecting management's confidence in the company's future [3] - The latest financial results showed sales growth exceeding 50% year-over-year, following previous growth rates of 46% and 36% in the last two quarters [4] MicroStrategy (MSTR) - MicroStrategy shares are highly volatile due to significant exposure to Bitcoin, with fluctuations ranging from a 15% increase to a 62% decrease over the past year [8] - An insider acquired 5,000 shares for nearly $800,000, indicating continued confidence despite volatility [8] - The company holds approximately 710,000 BTC, with an average acquisition cost of around $76,000 compared to Bitcoin's current price of approximately $89,000 [10] APi Group (APG) - APi Group shares have outperformed the market, gaining nearly 70% over the past year due to strong demand trends [11] - A director bought 3,000 shares for just under $120,000, nearly doubling their position [11] - For Q3 FY25, APG reported sales of $2.1 billion, a year-over-year increase of 14.2%, with adjusted EPS of $0.41, up 20.6% year-over-year [12]

Core Viewpoint - APi Group (APG) shares have experienced significant growth in 2025, driven by recognition of past performances, an acceleration in organic growth rates, and ambitious goals set for 2028 [1]. Group 1: Company Performance - APi Group has shown incredible momentum in its stock performance during 2025 [1]. - The company's organic growth rates have accelerated, contributing to its positive market perception [1]. Group 2: Future Outlook - APi Group has set ambitious goals for 2028, indicating a forward-looking strategy aimed at sustaining growth [1].

Core Insights - Apogee Therapeutics, Inc. is set to report interim results from its Phase 1b trial of APG777 for mild-to-moderate asthma on January 6, 2026, followed by a conference call and webcast at 8:00 a.m. ET [1] Company Overview - Apogee Therapeutics is a clinical-stage biotechnology company focused on developing optimized, novel biologics for the inflammatory and immunology (I&I) markets, including treatments for atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications [3] - The company's lead program, APG777, targets the treatment of AD, which is identified as the largest and least penetrated market within the I&I sector [3] - Apogee's antibody programs aim to address the limitations of existing therapies by utilizing established mechanisms of action and advanced antibody engineering to enhance properties such as half-life [3] - The company has four validated targets in its portfolio and is pursuing best-in-class efficacy and dosing through both monotherapies and combinations of its novel antibodies [3]

Core Viewpoint - Investors are increasingly seeking growth stocks that demonstrate above-average growth potential, particularly in the financial sector, to achieve exceptional returns, although identifying such stocks can be challenging due to their inherent risks and volatility [1] Group 1: Company Overview - APi (APG) is identified as a promising growth stock, supported by a favorable Growth Score and a top Zacks Rank [2] - The company has a historical EPS growth rate of 14.9%, with projected EPS growth of 14.6% for the current year, surpassing the industry average of 9.6% [5] Group 2: Financial Metrics - APi's year-over-year cash flow growth stands at an impressive 120.9%, significantly higher than the industry average of 2% [6] - The company's annualized cash flow growth rate over the past 3-5 years is 76.5%, compared to the industry average of 7.1% [7] Group 3: Earnings Estimates - The current-year earnings estimates for APi have been revised upward, with the Zacks Consensus Estimate increasing by 0.2% over the past month [9] - APi has achieved a Growth Score of B and a Zacks Rank of 2, indicating positive earnings estimate revisions and potential for outperformance [10]